Literature DB >> 6501314

Low-density lipoprotein receptor binding determinants switch from apolipoprotein E to apolipoprotein B during conversion of hypertriglyceridemic very-low-density lipoprotein to low-density lipoproteins.

W A Bradley, S L Hwang, J B Karlin, A H Lin, S C Prasad, A M Gotto, S H Gianturco.   

Abstract

Using thrombin and trypsin as probes, we determined: first, that low-density lipoprotein (LDL) receptor binding determinants switch from apolipoprotein (apo) E to apo-B within the very-low-density lipoprotein (VLDL) Sf 20-60 region of the metabolic cascade from VLDL1 (Sf 100-400) of hypertriglyceridemic (HTG) human subjects to LDL. Second, two different conformations of apo-E exist in HTG-VLDL Sf greater than 60, one accessible (greater than or equal to 1 mol/mol of particle) and one inaccessible (1-2 mol/mol) to both thrombin and the LDL receptor; normal VLDL (Sf greater than 60) have only the inaccessible conformation and therefore do not bind to the LDL receptor. Third, thrombin degrades apo-B into large fragments, three of which have electrophoretic mobilities similar to B-48, B-74, and B-26; this, however, has no effect on apo-B-mediated receptor binding. Fibroblast studies showed that thrombin could abolish receptor uptake of HTG-VLDL1 and HTG-VLDL2 (Sf 60-100), had little or no effect on HTG-VLDL3 (Sf 20-60), and no effect on uptake of intermediate-density lipoprotein (IDL) or LDL. Trypsin abolished the binding of HTG-VLDL1 and HTG-VLDL2, reduced that of HTG-VLDL3, but had little to no effect on IDL or LDL binding. Immunochemical techniques revealed that thrombin cleaved some apo-E into the E-22 and E-12 fragments; after trypsin treatment no apo-E was detected in any HTG-lipoprotein. Normal VLDL subclasses contained less apo-E than the corresponding HTG-VLDL subclasses and it was not cleaved by thrombin. Apo-B immunoreactivities of VLDL subclasses were not significantly changed after treatment with thrombin, although thrombin cleaved some of the B-100 of each VLDL subclass, and all apo-B in IDL and LDL, into 4-6 major large fragments. Trypsin converted all of the apo-B of each lipoprotein into smaller fragments (Mr less than 100,000). We conclude that apo-E of the thrombin-accessible conformation mediates uptake of HTG-VLDL1 and HTG-VLDL2 but that apo-B alone is sufficient to mediate receptor binding of IDL and LDL; the switch from apo-E to apo-B as the primary or sufficient binding determinant occurs within the VLDL3 (Sf 20-60) region of the metabolic cascade, where receptor binding first appears in VLDL subclasses from normal subjects.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6501314

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  21 in total

1.  Use of hydrophobicity profiles to predict receptor binding domains on apolipoprotein E and the low density lipoprotein apolipoprotein B-E receptor.

Authors:  H De Loof; M Rosseneu; R Brasseur; J M Ruysschaert
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

2.  Lipoprotein binding to cultured human hepatoma cells.

Authors:  F Krempler; G M Kostner; W Friedl; B Paulweber; H Bauer; F Sandhofer
Journal:  J Clin Invest       Date:  1987-08       Impact factor: 14.808

3.  The effects of ezetimibe and/or orlistat on triglyceride-rich lipoprotein metabolism in obese hypercholesterolemic patients.

Authors:  E S Nakou; T D Filippatos; A P Agouridis; C Kostara; E T Bairaktari; M S Elisaf
Journal:  Lipids       Date:  2010-04-09       Impact factor: 1.880

4.  Regulation of very low density lipoprotein apo B metabolism by dietary fat saturation and chain length in the guinea pig.

Authors:  G Abdel-Fattah; M L Fernandez; D J McNamara
Journal:  Lipids       Date:  1998-01       Impact factor: 1.880

5.  Two apolipoprotein E mimetic peptides with similar cholesterol reducing properties exhibit differential atheroprotective effects in LDL-R null mice.

Authors:  Shaila P Handattu; Gaurav Nayyar; David W Garber; Mayakonda N Palgunachari; Candyce E Monroe; Tamara D Keenum; Vinod K Mishra; Geeta Datta; G M Anantharamaiah
Journal:  Atherosclerosis       Date:  2012-11-02       Impact factor: 5.162

6.  Influence of apolipoprotein E polymorphism on apolipoprotein B-100 metabolism in normolipemic subjects.

Authors:  T Demant; D Bedford; C J Packard; J Shepherd
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

7.  Metabolism by human endothelial cells of very low density lipoprotein subfractions isolated from type 1 (insulin-dependent) diabetic patients.

Authors:  R L Klein; M F Lopes-Virella
Journal:  Diabetologia       Date:  1993-03       Impact factor: 10.122

8.  Distinct murine macrophage receptor pathway for human triglyceride-rich lipoproteins.

Authors:  S H Gianturco; A H Lin; S L Hwang; J Young; S A Brown; D P Via; W A Bradley
Journal:  J Clin Invest       Date:  1988-11       Impact factor: 14.808

9.  Absence of hyperlipidemia in LDL receptor-deficient mice having apolipoprotein B100 without the putative receptor-binding sequences.

Authors:  Lance A Johnson; Michael K Altenburg; Rosemary L Walzem; Lori T Scanga; Nobuyo Maeda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2008-07-10       Impact factor: 8.311

10.  Molecular mechanism of apolipoprotein E binding to lipoprotein particles.

Authors:  David Nguyen; Padmaja Dhanasekaran; Michael C Phillips; Sissel Lund-Katz
Journal:  Biochemistry       Date:  2009-04-07       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.